Overview

  • Product nameAnti-p53 antibody [PAb 240]
    See all p53 primary antibodies
  • Description
    Mouse monoclonal [PAb 240] to p53
  • SpecificityThis p53 monoclonal antibody recognizes both mutant and wild type conformational forms of p53 under denaturing conditions. The PAb 240 clone recognizes an epitope that is structurally hidden in the wild type conformation of p53 but becomes exposed by denaturation or in mutant conformations of p53 where point mutations in the TP53 gene alter the structure of the protein (Gannon JV et al., 1990; Stephen CW et al., 1992; Wang PL et al., 2001).
  • Tested applicationsSuitable for: IP, ICC/IF, WBmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Cow, Dog, Human, Monkey, Chinese hamster, Syrian hamster
  • Immunogen

    Gel-purified p53-beta-galactosidase fusion protein containing murine p53 from aa 14-389 (derived from pSV53C cDNA clone).

  • EpitopeThe epitope has been mapped between amino acids 213 and 217 on human and mouse p53.
  • Positive control
    • WB: A431 cell lysate. ICC-IF: A431 cells.
  • General notes

    This p53 antibody has been knockout validated in Western blot. The expected band was seen in wild type HCT116 cells treated with the DNA damaging agent irinotecan and no band was seen in TP53 knockout HCT116 cells.

    We recommend using 3% milk as the blocking agent for Western blot.

    This antibody is available as an azide-free product (see ab176243).

Properties

Applications

Our Abpromise guarantee covers the use of ab26 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IP Use a concentration of 10 µg/ml.
ICC/IF Use a concentration of 0.5 - 1 µg/ml.
WB Use a concentration of 1 - 5 µg/ml. Detects a band of approximately 53 kDa (predicted molecular weight: 53 kDa).

We recommend using 3% milk as the blocking agent for Western blot.

Target

  • FunctionActs as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Implicated in Notch signaling cross-over. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis.
  • Tissue specificityUbiquitous. Isoforms are expressed in a wide range of normal tissues but in a tissue-dependent manner. Isoform 2 is expressed in most normal tissues but is not detected in brain, lung, prostate, muscle, fetal brain, spinal cord and fetal liver. Isoform 3 is expressed in most normal tissues but is not detected in lung, spleen, testis, fetal brain, spinal cord and fetal liver. Isoform 7 is expressed in most normal tissues but is not detected in prostate, uterus, skeletal muscle and breast. Isoform 8 is detected only in colon, bone marrow, testis, fetal brain and intestine. Isoform 9 is expressed in most normal tissues but is not detected in brain, heart, lung, fetal liver, salivary gland, breast or intestine.
  • Involvement in diseaseNote=TP53 is found in increased amounts in a wide variety of transformed cells. TP53 is frequently mutated or inactivated in about 60% of cancers. TP53 defects are found in Barrett metaplasia a condition in which the normally stratified squamous epithelium of the lower esophagus is replaced by a metaplastic columnar epithelium. The condition develops as a complication in approximately 10% of patients with chronic gastroesophageal reflux disease and predisposes to the development of esophageal adenocarcinoma.
    Defects in TP53 are a cause of esophageal cancer (ESCR) [MIM:133239].
    Defects in TP53 are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is an autosomal dominant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a sarcoma at any age. Other clinical definitions for LFS have been proposed (PubMed:8118819 and PubMed:8718514) and called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers.
    Defects in TP53 are involved in head and neck squamous cell carcinomas (HNSCC) [MIM:275355]; also known as squamous cell carcinoma of the head and neck.
    Defects in TP53 are a cause of lung cancer (LNCR) [MIM:211980].
    Defects in TP53 are a cause of choroid plexus papilloma (CPLPA) [MIM:260500]. Choroid plexus papilloma is a slow-growing benign tumor of the choroid plexus that often invades the leptomeninges. In children it is usually in a lateral ventricle but in adults it is more often in the fourth ventricle. Hydrocephalus is common, either from obstruction or from tumor secretion of cerebrospinal fluid. If it undergoes malignant transformation it is called a choroid plexus carcinoma. Primary choroid plexus tumors are rare and usually occur in early childhood.
    Defects in TP53 are a cause of adrenocortical carcinoma (ADCC) [MIM:202300]. ADCC is a rare childhood tumor of the adrenal cortex. It occurs with increased frequency in patients with the Beckwith-Wiedemann syndrome and is a component tumor in Li-Fraumeni syndrome.
  • Sequence similaritiesBelongs to the p53 family.
  • DomainThe nuclear export signal acts as a transcriptional repression domain. The TADI and TADII motifs (residues 17 to 25 and 48 to 56) correspond both to 9aaTAD motifs which are transactivation domains present in a large number of yeast and animal transcription factors.
  • Post-translational
    modifications
    Acetylated. Acetylation of Lys-382 by CREBBP enhances transcriptional activity. Deacetylation of Lys-382 by SIRT1 impairs its ability to induce proapoptotic program and modulate cell senescence.
    Phosphorylation on Ser residues mediates transcriptional activation. Phosphorylated by HIPK1 (By similarity). Phosphorylation at Ser-9 by HIPK4 increases repression activity on BIRC5 promoter. Phosphorylated on Thr-18 by VRK1. Phosphorylated on Ser-20 by CHEK2 in response to DNA damage, which prevents ubiquitination by MDM2. Phosphorylated on Thr-55 by TAF1, which promotes MDM2-mediated degradation. Phosphorylated on Ser-46 by HIPK2 upon UV irradiation. Phosphorylation on Ser-46 is required for acetylation by CREBBP. Phosphorylated on Ser-392 following UV but not gamma irradiation. Phosphorylated upon DNA damage, probably by ATM or ATR. Phosphorylated on Ser-15 upon ultraviolet irradiation; which is enhanced by interaction with BANP.
    Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40 small T antigen inhibits the dephosphorylation by the AC form of PP2A.
    May be O-glycosylated in the C-terminal basic region. Studied in EB-1 cell line.
    Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal degradation. Ubiquitinated by RFWD3, which works in cooperation with MDM2 and may catalyze the formation of short polyubiquitin chains on p53/TP53 that are not targeted to the proteasome. Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which leads to proteasomal degradation. Deubiquitinated by USP10, leading to its stabilization. Ubiquitinated by TRIM24, which leads to proteasomal degradation. Ubiquitination by TOPORS induces degradation. Deubiquitination by USP7, leading to stabilization. Isoform 4 is monoubiquitinated in an MDM2-independent manner.
    Monomethylated at Lys-372 by SETD7, leading to stabilization and increased transcriptional activation. Monomethylated at Lys-370 by SMYD2, leading to decreased DNA-binding activity and subsequent transcriptional regulation activity. Lys-372 monomethylation prevents interaction with SMYD2 and subsequent monomethylation at Lys-370. Dimethylated at Lys-373 by EHMT1 and EHMT2. Monomethylated at Lys-382 by SETD8, promoting interaction with L3MBTL1 and leading to repress transcriptional activity. Demethylation of dimethylated Lys-370 by KDM1A prevents interaction with TP53BP1 and represses TP53-mediated transcriptional activation.
    Sumoylated by SUMO1.
  • Cellular localizationCytoplasm; Cytoplasm. Nucleus. Nucleus > PML body. Endoplasmic reticulum. Interaction with BANP promotes nuclear localization. Recruited into PML bodies together with CHEK2; Nucleus. Cytoplasm. Localized in both nucleus and cytoplasm in most cells. In some cells, forms foci in the nucleus that are different from nucleoli; Nucleus. Cytoplasm. Localized in the nucleus in most cells but found in the cytoplasm in some cells; Nucleus. Cytoplasm. Localized mainly in the nucleus with minor staining in the cytoplasm; Nucleus. Cytoplasm. Predominantly nuclear but localizes to the cytoplasm when expressed with isoform 4 and Nucleus. Cytoplasm. Predominantly nuclear but translocates to the cytoplasm following cell stress.
  • Information by UniProt
  • Database links
  • Alternative names
    • Antigen NY-CO-13 antibody
    • BCC7 antibody
    • Cellular tumor antigen p53 antibody
    • FLJ92943 antibody
    • LFS1 antibody
    • Mutant tumor protein 53 antibody
    • p53 antibody
    • p53 tumor suppressor antibody
    • P53_HUMAN antibody
    • Phosphoprotein p53 antibody
    • Tp53 antibody
    • Transformation related protein 53 antibody
    • TRP53 antibody
    • Tumor protein 53 antibody
    • Tumor protein p53 antibody
    • Tumor suppressor p53 antibody
    see all

Anti-p53 antibody [PAb 240] images

  • All lanes : Mouse monoclonal [PAb 240] to p53 (ab26) at 5 µg/ml

    Lane 1 : Wild-type HCT116 cell lysate at 30 µg
    Lane 2 : Wild-type HCT116 + irinotecan (10 µM, 24 hours) cell lysate at 30 µg
    Lane 3 : p53 knockout HCT116 cell lysate at 30 µg
    Lane 4 : p53 knockout HCT116 + irinotecan (10 µM, 24 hours) cell lysate at 30 µg
    Lane 5 : A431 cell lysate (positive control) at 20 µg
    Lane 6 : Saos-2 cell lysate (negative control) at 20 µg
    Lane 7 : MEF cell lysate at 20 µg

    Developed using the ECL technique

    Performed under reducing conditions.

    Predicted band size : 53 kDa

    Merged (red and green) signal.
    Ab26 was shown to specifically react with p53, when p53 knockout samples were used. Wild-type and p53 knockout samples, positive and negative controls were subjected to SDS-PAGE. Ab26 and ab181602(loading control to GAPDH) were diluted 5 μg/mL and 1/10,000 respectively and incubated overnight at 4°C. Blots were developed with goat anti-rabbit IgG (H + L) and goat anti-mouse IgG (H + L) secondary antibodies at 1/10,000 dilution for 1 h at room temperature before imaging.

    Wild-type and p53 knockout HCT116 cell lysates were kindly provided by a collaborator. 

  • ab26 stained in A431 cells. Cells were fixed with 4% paraformaldehyde (10min) at room temperature and incubated with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% triton for 1h at room temperature to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with ab26 at 1µg/ml and ab6046 (Rabbit polyclonal to beta tubulin) at 1ug/ml overnight at +4°C. The secondary antibodies were ab150177 (colored green) used at 1 ug/ml and ab150087 (pseudo-colored red) used at 2ug/ml for 1hour at room temperature. DAPI was used to stain the cell nuclei (colored blue) at a concentration of 1.43µM for 1hour at room temperature.



  • Predicted band size : 53 kDa

    Primary: All Lanes: Anti-p53 antibody (ab26) at 5 µg/mL. Lane 1: MW marker. Lane 2: NIH/3T3 cells treated with vehicle for 24 hours. Lane 3: NIH/3T3 cells treated with 1 µM doxorubicin for 24 hours Secondary: All Lanes: HRP-conjugated VeriBlot anti-Mouse IgG (ab131368) 1:1000. Lysates at 20 µg/lane. Performed under denaturing conditions. Developed using ECL technique. Blocking buffer: 5% milk in PBS.

  • Lanes 1 - 2 : Anti-p53 antibody [PAb 240] (ab26) at 1 µg/ml
    Lanes 3 - 4 : Anti-p53 antibody [PAb 240] (ab26) at 5 µg/ml

    Lane 1 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate
    Lane 2 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate
    Lane 3 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate
    Lane 4 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate

    Lysates/proteins at 20 µg per lane.

    Secondary
    Goat polyclonal to Mouse IgG - H&L - Pre-Adsorbed (HRP) at 1/5000 dilution
    Developed using the ECL technique

    Performed under reducing conditions.

    Predicted band size : 53 kDa


    Exposure time : 4 minutes

    Lanes 1-2: 1% BSA blocking buffer

    Lanes 3-4: 3% Milk blocking buffer

     

    We recommend using 3% milk as the blocking agent for Western blot.

  • All lanes : Anti-p53 antibody [PAb 240] (ab26) at 5 µg/ml

    Lane 1 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate
    Lane 2 : Hela Whole Cell Lysate - Bleomycin Treated (40U/ml)

    Lysates/proteins at 20 µg per lane.

    Secondary
    Goat Anti-Mouse IgG H&L (HRP) preadsorbed (ab97040) at 1/5000 dilution
    Developed using the ECL technique

    Performed under reducing conditions.

    Predicted band size : 53 kDa


    Exposure time : 4 minutes
  • Anti-p53 antibody [PAb 240] (ab26) at 1 µg/ml + HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate at 10 µg

    Secondary
    Goat Anti-Mouse IgG H&L (HRP) preadsorbed (ab97040) at 1/50000 dilution
    Developed using the ECL technique

    Performed under reducing conditions.

    Predicted band size : 53 kDa
    Observed band size : 53 kDa


    Exposure time : 8 minutes

    This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab26 overnight at 4°C. Antibody binding was detected using an anti-mouse HRP secondary antibody, and visualised using ECL development solution ab133406

  • All lanes : Anti-p53 antibody [PAb 240] (ab26) at 1/2000 dilution

    Lane 1 : Human breast cancer cell-line, MCF7 cells (p53 WT), whole cell lysate
    Lane 2 : Human breast cancer cell-line, MDA231 cells (p53 Mutant), whole cell lysate

    Lysates/proteins at 20 µg per lane.

    Secondary
    HRP conjugated donkey anti-mouse antibody at 1/5000 dilution
    Developed using the ECL technique

    Performed under reducing conditions.

    Predicted band size : 53 kDa
    Observed band size : 53 kDa
    Additional bands at : 72 kDa (possible non-specific binding).

    Exposure time : 10 seconds

    This image is courtesy of an Abreview submitted by Dr Cherie Blenkiron

    See Abreview



  • Predicted band size : 53 kDa

    MALME-3M cells were incubated at 37°C for 24h with vehicle control (0 μM) and 1 μM andrographolide (ab120636). Increased expression of p53 in MALME-3M cells correlates with an increase in andrographolide concentration, as described in literature.

    Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 10μg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 5% BSA before being incubated with ab26 at 5 μg/ml andab8227at 1 μg/ml overnight at 4°C. Antibody binding was detected using an anti-mouse antibody conjugated to HRP (ab97040) at 1/10000 dilution and visualised using ECL development solution.


  • Developed using the ECL technique

    Performed under reducing conditions.

    Predicted band size : 53 kDa


    Exposure time : 20 minutes

    K562 cells were incubated at 37 °C for 4h with vehicle control (0 μM) and 15 nM of neurokinin A (ab120185). Increased expression of p53 (ab26) correlates with an increase in neurokinin A concentration, as described in literature.
    Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 20 μg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 3% milk before being incubated with ab26 at 5 μg/ml and ab8227 at 1 μg/ml overnight at 4°C. Antibody binding was detected using an anti-mouse antibody conjugated to HRP (ab97040) at 1/10000 dilution and visualised using ECL development solution.

References for Anti-p53 antibody [PAb 240] (ab26)

This product has been referenced in:
  • Sun J  et al. Dendrobium candidum inhibits MCF-7 cells proliferation by inducing cell cycle arrest at G2/M phase and regulating key biomarkers. Onco Targets Ther 9:21-30 (2016). WB ; Human . Read more (PubMed: 26730200) »
  • Chen CC  et al. The matricellular protein CCN1 suppresses hepatocarcinogenesis by inhibiting compensatory proliferation. Oncogene 35:1314-23 (2016). IHC-P ; Human . Read more (PubMed: 26028023) »

See all 50 Publications for this product

Product Wall

Thank you very much for your interest in ab26.

To our knowledge, ab26 has not been tested in IHC-P using Bouin fixation, however I don't see a reasonwhy it wouldn't work. Most customers have tried formaldehyde, PFA, and 10% formalin.
Read More

Gracias por contactarnos.


El anticuerpo ab26 reconoce la región comprendida entre los amino ácidos 213 y 217 de p53 humano. El anticuerpo identifica las dos formas mutantes y la forma “wild type” de la prote&iac...

Read More

Thank you for your call today and for your patience while I have looked through some literature regarding p53 localization.

I found a few publications showing cytoplasmic staining of p53 in the cornea (see attached) which all seem to be from ...

Read More

Expiration date: 18. October 2012

DISCOUNT CODEs:

ab26 cat : 0000

ab7980 IHC-Fr : 0000
ab90363 IHC-Fr : 000
ab5714 IHC-Fr : 000

ab97068 IHC-Fr : 00000

I am very pleased to hear your customer w...

Read More

Thank you for contacting us.
I am sorry we are unable to resolve your inquiry at Abcam. Please contact our distributor Kimera with all the details. They will be able to resolve the case for you.

I hope this information is nevertheless he...

Read More
Abcam guarantees this product to work in the species/application used in this Abreview.
Application Western blot
Sample Human Cell lysate - whole cell (HCT116)
Loading amount 20 µg
Specification HCT116
Treatment 100 µM 5-FU
Gel Running Conditions Reduced Denaturing (10 %)
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
Username

Mr. taeshin kim

Verified customer

Submitted May 16 2012

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Western blot
Sample Mouse Tissue lysate - whole (thymus, bone marrow, spleen)
Loading amount 30 µg
Specification thymus, bone marrow, spleen
Gel Running Conditions Reduced Denaturing
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
Username

Mr. taeshin kim

Verified customer

Submitted May 14 2012

Thank you very much for your reply.

I'm sending a free of charge vial of ab28 on the order ***, and this order should arrive tomorrow. Please keep me updated about the results using this replacement antibody.

If there is anything el...

Read More

Thank you for your reply and for keeping me updated. I'm sorry to hear that the results were so poor with this antibody.

I would be happy to send a replacement antibody that might work better. We do have several other p53 antibodies with rat ...

Read More

Thank you for your call today and for your questions about ab26.

As we discussed, I would be happy to help if you have any trouble using ab26 in your Western blots. Please keep me updated aboutyour results and let me know if you have any ques...

Read More

41-50 of 79 Abreviews or Q&A

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"